期刊文献+

Bcr-abl阴性骨髓增殖性疾病患者的jak2v617f点突变与socs3基因表达的相关性 被引量:1

Relationship Between Socs3 mRNA Expression and Jak2v617f Point Mutation in Bcr-abl Negative Patients with Myelo-proliferative Disease
下载PDF
导出
摘要 本研究探讨bcr-abl阴性MPD患者中的jak2v617f点突变与socs3基因表达的相关性。选择62例bcr-abl阴性MPD患者(PV26例、ET26例、IMF9例、CNL1例)为研究组,CML20例、AL10例、健康志愿者15名为对照组;用AS-PCR检测各组患者jak2v617f的突变情况,PCR产物纯化后测序以发现突变患者;用RT-PCR方法检测各组socs3 mRNA的表达情况;分析bcr-abl阴性MPD患者中jak2v617f点突变阳性组及阴性组之间socs3 mRNA表达的相关性。结果发现,在62例bcr-abl阴性MPD患者中44例jak2v617f突变阳性(PV23例、ET15例、IMF5例、CNL1例),18例突变阴性。对照组均为阴性。44例突变阳性组中39例表达socs3 mRNA。18例突变阴性组中10例表达socs3 mRNA。jak2v617f突变阳性组与阴性组患者的socs3 mRNA表达率有显著性差异(χ2值=8.44,p<0.005);jak2v617f突变阳性组与阴性组两组患者的socs3 mRNA表达水平也有显著性差异(t值2.167,p=0.035)。结论bcr-abl阴性MPD患者中jak2v617f点突变阳性与阴性组socs3 mRNA的表达率及表达水平均有显著性差异。 To investigate the relationship between socs3 mRNA expression and jak2v617f point mutation in bcr-abl negative patients with myelo-proliferative disease (MPD), 62 bcr-abl negative MPD patients( 26 cases of PV ,26 cases of ET ,9 cases of IMF, and one case of CNL)were arranged as experiment group, and the others (20 cases of CML, 10 cases of AL and 15 healthy volunteers) were arranged as control group. All the diagnosis had been made according to the 2001 WHO criteria, jak2v617f point mutation was detected by AS-PCR and confirmed by direct sequencing. The expression level of socs3 mRNA was measured by RT-PCR. The association jak2v617f point mutation with socs3 mRNA expression in bcr-abl negative MPD patients was observed and analyzed. The results showed that among 62 bcr-abl negative MPD patients,the somatic jak2v617f point mutation was positive in 44 patients (PV 23, ET 15, IMF 5, CNL 1 ) while negative in the other 18 patients and control group. The expression of socs3 mRNA could be detected in 39 patients from 44 jak2v617f mutation positive patients and in 10 patients from 18 jak2v617f mutation-negative patients. There was a statistically significant difference in socs3 mRNA expression rates between jak2v617f mutation positive and negative group( x^2 = 8. 44 ,p 〈 0. 005 ). There was a statistically significant difference in socs3 mRNA expression levels between jak2v617f mutation positive and negative groups(p = 0.035 ). It is concluded that there is a statistically significant difference in the expression level of socs3 mRNA in the patients between jak2v617f mutation positive group and negative group.
出处 《中国实验血液学杂志》 CAS CSCD 2008年第3期479-483,共5页 Journal of Experimental Hematology
基金 河北省衡水市科技局资助项目,编号07008A
关键词 骨髓增殖性疾病 JAK2V617F socs3基因 bcr—ab1基因 基因突变 myeloproliferative disease jak2v617f socs3 gene bcr-abl gene gene mutation
  • 相关文献

参考文献11

  • 1Dalai I, Arpaia E, Dadi H, et al. Cloning and characterization of the human homolog of mouse Jak2. Blood,1998; 91:844 -851.
  • 2Saharinen P, Takaluoma K, Silvennoinen O. Regulation of the Jak2 tyrosine kinase by its pseudokinase domain. Mol Cell Bio, 2000 ; 20 : 3387 - 3395.
  • 3Baxter EJ, Scott LM, Campbell PJ, et al. Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative diseases. Lancet, 2005; 365(9464) : 1054 - 1061.
  • 4Levine RL, Wadleigh M, Cools J, et al. Activating mutation of the tyrosine ldnase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell, 2005 ; 7 : 387 - 397.
  • 5Kralovics R, Passamonti F, Buser AS, et al. A gain-of-function mutation of JAK2 in myeloproliferative disorders. N Engl J Med, 2005 ; 352 : 1779 - 1790.
  • 6James C, Ugo V, LeCouedic JP, et al. A unique clonal JAK2 mutation leading to constitutive signaling causes polycythaemia vera. Nature, 2005 ; 434(7037) : 1144 - 1148.
  • 7Jones AV, Kreil S, Zoi K, et al. Widespread occurrence of the JAK2V617 mutation in chronic myeloproliferative disorders. Blood, 2005; 106:2162-2168.
  • 8Kralovics R,Teo SS, Buser AS, et al. Altered gene expression in myeloproliferative disorders correlates with activation of signaling by the V617F mutation of Jak2. Blood, 2005 ; 106 : 3374 - 3376.
  • 9Hookharn MB, Elliott J, Suessmuth Y, et al. The myeloproliferative disorder-associated JAK2V617F mutant escapes negative regulation by suppressor of cytokine signaling 3. Blood, 2007; 109:4924 - 4929.
  • 10Limnander A, Danial NN, Rothman PB. v-Abl signaling disrupts SOCS1 function in tranformed pre-B cells. Mol Cell, 2004; 15: 329 - 341.

同被引文献36

  • 1张莉红,徐永健,张珍祥.SOCS在哮喘发病中的作用[J].国外医学(呼吸系统分册),2005,25(9):663-664. 被引量:1
  • 2王念鸿,郭晓蕙.SOCS-3与胰岛素抵抗[J].国外医学(内分泌学分册),2005,25(6):409-411. 被引量:5
  • 3邹大进,吴鸿.腹型肥胖致胰岛素抵抗的机制及治疗展望[J].中国糖尿病杂志,2006,14(4):309-312. 被引量:39
  • 4Wincewicz A,Sulkowska M,Rutkowski R,et al.STAT1 and STAT3as intracellular regulators of vascular remodeling[J].Eur J Intern Med,2007,18(4):267-271.
  • 5Endo TA,Masuhara M,Yokouchi M,et al.A new protein containing an SH2domain that inhibits JAK kinases[J].Nature,1997,387(6636):921-924.
  • 6Krebs DL,Hilton DJ.SOCS:physiological suppressors of cytokine signaling[J].J Cell Sci,2000,113(pt16):2813-2819.
  • 7Kamizono S,Hanada T,Yasukawa H,et al.The SOCS box of SOCS-1accelerates ubiquitin-dependent proteolysis ofTEL-JAK2[J].J Biol Chem,2001,276(14):12530-12538.
  • 8senn JJ,Klover PJ,Nowak IA,et al.Suppressor of cytokine signaling3(SOCS3),a potential mediator of interleukin-6-dependent insulin resistance in hepatocytes[J].J Biol Chem,2003,278(16):13740-13746.
  • 9Chen T,Huang Z,Wang L,et al.MicroRNA-125a-5p partly regulates the inflammatory response,lipid uptake,and ORP9expression in ox-LDL stimulated monocyte/mac-rophages[J].Cardiovasc Res,2009,83(1):131-139.
  • 10Wesoly J,Sikorski K,Lee CK,et al.Suppressor of cyto-kine signaling and accelerated atherosclerosis in kidney dis-ease[J].Acta Biochim Pol,2010,57(3):251-260.

引证文献1

二级引证文献15

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部